Thursday, August 13, 2020

WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility

State-of-the-art facility expands WuXi STA's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial Shanghai, January 3, 2020: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – today announced the...

TDI Serves as a Bridge Between Academia and Industry, Leveraging All It Needs for Innovation

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) and WuXi AppTec Content Team The translation of academic discoveries into therapeutic products remains an issue despite passage of the Bayh-Dole Act (or Patent and Trademark Law Amendments...

WuXi Global Forum 2020 – Advancing Breakthroughs for Patients

Now in its eighth year, the WuXi Global Forum at the J.P. Morgan Healthcare Conference brings together thousands of leaders to promote new thinking on a global stage as we strive to provide transformative solutions for patients. We welcome you to join the conversation! WuXi...

WuXi ATU and GeneMedicine Sign Development and Manufacturing Agreement for Oncolytic Virus Products

Shanghai and Seoul, November 29, 2019 - WuXi ATU Co., Ltd., (WuXi ATU) - a subsidiary of WuXi AppTec, and GeneMedicine - a South Korea-based gene therapy biotechnology company, have formed a strategic partnership for the development and manufacturing of oncolytic virus...

WuXi AppTec’s Lab Testing Division Expands Toxicology Facility in Suzhou, China

WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced its Lab Testing Division (LTD) has expanded the Suzhou safety assessment facility by increasing toxicology capacity by 80%...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS